Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on the development of transformative medicines for the treatment of serious diseases. Founded in 2008, Arrowhead has made significant strides in the field of RNA interference (RNAi) therapeutics, positioning itself as a leader in this innovative industry. With a strong emphasis on precision medicine, Arrowhead's core products include ARO-HBV and ARO-AAT, which target chronic hepatitis B and alpha-1 antitrypsin deficiency, respectively. These therapies are distinguished by their ability to silence disease-causing genes, offering unique treatment options that address unmet medical needs. Arrowhead's commitment to advancing healthcare is reflected in its robust pipeline and strategic partnerships, solidifying its market position as a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Arrowhead Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arrowhead Pharmaceuticals, Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Arrowhead Pharmaceuticals, Inc.'s reported carbon emissions
Arrowhead Pharmaceuticals, Inc., headquartered in the US, currently does not have available carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Arrowhead Pharmaceuticals may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate commitments, often setting science-based targets to align with global climate goals. However, without specific emissions data or reduction initiatives from Arrowhead Pharmaceuticals, it is unclear how the company is addressing its environmental impact. As the industry evolves, it is essential for companies like Arrowhead Pharmaceuticals to consider implementing robust climate strategies to enhance transparency and contribute to broader sustainability efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Arrowhead Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
